Catalyst Pharma Reports Record Q2 2025 Financial Results

Catalyst Pharma ( (CPRX) ) has issued an update.

On August 6, 2025, Catalyst Pharmaceuticals reported record financial results for the second quarter and first half of 2025, with total revenues reaching $146.6 million in Q2, marking a 19.4% year-over-year increase. The company highlighted strong performance across its product portfolio, particularly noting AGAMREE’s significant growth following its 2024 launch, while FYCOMPA faced a slight revenue decline due to generic competition. Catalyst’s robust cash position and reaffirmed revenue guidance reflect its strategic execution and sustained demand, positioning it well for future growth.

The most recent analyst rating on (CPRX) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on Catalyst Pharma stock, see the CPRX Stock Forecast page.

Spark’s Take on CPRX Stock

According to Spark, TipRanks’ AI Analyst, CPRX is a Outperform.

Catalyst Pharma’s strong financial performance and positive earnings call are the most significant factors driving the score. The company’s strategic initiatives and solid balance sheet support its growth prospects. Technical analysis presents some caution, but overall, the stock is well-positioned for continued success.

To see Spark’s full report on CPRX stock, click here.

More about Catalyst Pharma

Catalyst Pharmaceuticals, Inc. operates in the pharmaceutical industry, focusing on developing and commercializing innovative therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. Its primary products include FIRDAPSE, AGAMREE, and FYCOMPA, targeting conditions such as Lambert-Eaton myasthenic syndrome and epilepsy.

Average Trading Volume: 1,273,015

Technical Sentiment Signal: Buy

Current Market Cap: $2.71B

See more data about CPRX stock on TipRanks’ Stock Analysis page.